Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432

Clinical Cancer Research

Volumn 18, Issue 10, 2012, Pages 2954-2963

  LoRusso, Patricia M ^a   Venkatakrishnan, Karthik ^b   Ramanathan, Ramesh K ^c   Sarantopoulos, John ^d   Mulkerin, Daniel ^e   Shibata, Stephen I ^f   Hamilton, Anne ^g   Dowlati, Afshin ^h   Mani, Sridhar ⁱ   Rudek, Michelle A ^j   Takimoto, Chris H ^d   Neuwirth, Rachel ^b   Esseltine, Dixie Lee ^b   Ivy, Percy ^k  

^a KARMANOS CANCER INSTITUTE   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d CTRC Institute for Drug Development   (United States)

^e UNIVERSITY OF WISCONSIN   (United States)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^g ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^h CASE WESTERN RESERVE UNIVERSITY   (United States)

ⁱ ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^j JOHNS HOPKINS UNIVERSITY   (United States)

^k NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB;

ADULT; ADVANCED CANCER; ADVERSE OUTCOME; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; BREAST CANCER; CLINICAL EVALUATION; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; HEAD AND NECK CANCER; HUMAN; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LIVER FUNCTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHODGKIN LYMPHOMA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SARCOMA; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTE COUNT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DRUG DOSAGE CALCULATIONS; FEMALE; HUMANS; LIVER; LIVER DISEASES; MALE; MIDDLE AGED; NEOPLASMS; PYRAZINES;

EID: 84861130132     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2873     Document Type: Article

References (37)

1. Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest 2004;22:304-11. (Pubitemid 38725184)
2. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004;5:417-21. (Pubitemid 38610244) (Pubitemid 38610244)
3. Boccadoro M, Morgan G, Cavenagh J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int 2005;5:18.
4. Millennium Pharmaceuticals Inc. VELCADE® (bortezomib) for Injection. Prescribing information. Cambridge, MA: Millennium Pharmaceuticals, Inc; 2011 Issued November, Rev 12.
5. Janssen-Cilag International N.V. VELCADE® (bortezomib). Summary of product characteristics. Beerse, Belgium: Janssen-Cilag International N.V; 2009.
6. Labutti J, Parsons I, Huang R, Miwa G, Gan LS, Daniels JS. Oxidative deboronation of the peptide boronic acid proteasome inhibitor bortezomib: contributions from reactive oxygen species in this novel cytochrome P450 reaction. Chem Res Toxicol 2006;19:539-46.
7. Pekol T, Daniels JS, Labutti J, Parsons I, Nix D, Baronas E, et al. Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites. Drug Metab Dispos 2005;33:771-7. (Pubitemid 40686630) (Pubitemid 40686630)
8. Uttamsingh V, Lu C, Miwa G, Gan LS. Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug Metab Dispos 2005;33:1723-8. (Pubitemid 41539972) (Pubitemid 41539972)
9. Venkatakrishnan K, Rader M, Ramanathan RK, Ramalingam S, Chen E, Riordan W, et al. Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study. Clin Ther 2009;31:2444-58.
10. Quinn DI, Nemunaitis J, Fuloria J, Britten CD, Gabrail N, Yee L, et al. Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. Clin Pharmacokinet 2009;48:199-209.
11. Leal TB, Remick SC, Takimoto CH, Ramanathan RK, Davies A, Egorin MJ, et al. Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. Cancer Chemother Pharmacol 2011;68:1439-47.
12. Reece DE, Sullivan D, Lonial S, Mohrbacher AF, Chatta G, Shustik C, et al. Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. Cancer Chemother Pharmacol 2011;67:57-67.
13. Ramalingam SS, Kummar S, Sarantopoulos J, Shibata S, Lorusso P, Yerk M, et al. Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. J Clin Oncol 2010;28:4507-12.
14. Ramanathan RK, Egorin MJ, Takimoto CH, Remick SC, Doroshow JH, LoRusso PA, et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol 2008;26:563-9. (Pubitemid 351264349) (Pubitemid 351264349)
15. Synold TW, Takimoto CH, Doroshow JH, Gandara D, Mani S, Remick SC, et al. Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res 2007;13:3660-6. (Pubitemid 46955130) (Pubitemid 46955130)
16. Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ. Proteasome inhibition measurements: clinical application. Clin Chem 2000;46:673-83. (Pubitemid 30318423) (Pubitemid 30318423)
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
18. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
19. Moreau P, Coiteux V, Hulin C, Leleu X, van de Velde H, Acharya M, et al. Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. Haematologica 2008;93:1908-11.
20. Baker SD, van Schaik RH, Rivory LP, Ten Tije AJ, Dinh K, Graveland WJ, et al. Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res 2004;10:8341-50. (Pubitemid 40053395) (Pubitemid 40053395)
21. Alberts SR, Foster NR, Morton RF, Kugler J, Schaefer P, Wiesenfeld M, et al. PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study. Ann Oncol 2005;16:1654-61. (Pubitemid 41510140) (Pubitemid 41510140)
22. Engel RH, Brown JA, Von Roenn JH, O'Regan RM, Bergan R, Badve S, et al. A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience. Cancer Invest 2007;25:733-7. (Pubitemid 350223168) (Pubitemid 350223168)
23. Fanucchi MP, Fossella FV, Belt R, Natale R, Fidias P, Carbone DP, et al. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-smallcell lung cancer. J Clin Oncol 2006;24:5025-33. (Pubitemid 46631406) (Pubitemid 46631406)
24. Hegewisch-Becker S, Sterneck M, Schubert U, Rogiers X, Guerciolini R, Pierce JE, et al. Phase I/II trial of bortezomib in patients with unresectable hepatocellular carcinoma (HCC). J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004:4089.
25. Lara PN Jr, Chansky K, Davies AM, Franklin WA, Gumerlock PH, Guaglianone PP, et al. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327). J Thorac Oncol 2006;1:996-1001. (Pubitemid 47181369) (Pubitemid 47181369)
26. Mackay H, Hedley D, Major P, Townsley C, Mackenzie M, Vincent M, et al. A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clin Cancer Res 2005;11:5526-33. (Pubitemid 41060829) (Pubitemid 41060829)
27. Di Bella N, Taetle R, Kolibaba K, Boyd T, Raju R, Barrera D, et al. Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood 2010;115:475-80.
28. Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de VS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006;24:4867-74. (Pubitemid 46655613) (Pubitemid 46655613)
29. Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP, et al. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood 2009;114:1489-97.
30. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98. (Pubitemid 41007864)
31. Richardson PG, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Munshi N, et al. Bortezomib in the front-line treatment of multiple myeloma. Expert Rev Anticancer Ther 2008;8:1053-72.
32. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-17.
33. Treon SP, Hunter ZR, Matous J, Joyce RM, Mannion B, Advani R, et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res 2007;13:3320-5. (Pubitemid 46944918) (Pubitemid 46944918)
34. Bhandari MS, Mazumder A, Vesole DH. Liver involvement in multiple myeloma. Clin Lymphoma Myeloma 2007;7:538-40. (Pubitemid 350043492)
35. Rahhal FE, Schade RR, Nayak A, Coleman TA. Hepatic failure caused by plasma cell infiltration in multiple myeloma. World J Gastroenterol 2009;15:2038-40.
36. Gomyo H, Kagami Y, Kato H, Kawase T, Ohshiro A, Oyama T, et al. Primary hepatic follicular lymphoma: a case report and discussion of chemotherapy and favorable outcomes. J Clin Exp Hematop 2007;47:73-7.
37. Lai R, Medeiros LJ. Pathologic diagnosis of mantle cell lymphoma. Clin Lymphoma 2000;1:197-206.